According to VCBeat, Quanrong (Shanghai) Pharmaceutical Technology Development Co., Ltd. ("Oceanus Plus") has completed the Series A+ financing of tens of millions yuan, led by Med-Fine Capital. WinX Capital acted as the financial adviser.
Oceanus Plus is a SaaS company providing services of clinical trials, such as the clinical trial management system. Oceanus Plus is committed to improving the quality and efficiency of clinical researches.
Oceanus Plus provides comprehensive solutions to help enterprises and hospitals achieve routing and automation in healthcare project management and others. On the basis of the requirements of different regulatory authorities, the company launches products for quality management used in drugs, medical devices, and diagnostic reagents, in accordance with international and Chinese GCP specifications. It provides a full range of services in phase I to IV clinical research, IIT (investigator-initiated trials), RWE (real-world researches), and others.
At the beginning of its establishment, Oceanus Plus has got strategic investment from the Site Management Organization(SMO) company ChinPlus, and the Contract Research Organization (CRO) company Tigermed. So far, the company has cooperated with many leading SMO and CRO companies in the industry in a long term, developing rapidly in products, technologies, services, and applications in hospitals.
Oceanus Plus has built a product system with the S-Trial+ clinical trial central process management platform and the O-trial+ clinical trial execution management platform as the core, which can be applied in more clinical services. The company has passed the ISO27001, ISO13485 certification, in line with the requirements of the level three national information security protection.
Regarding this round of financing, Yang Fan, founder of Oceanus Plus, said that they are confident that the company can provide better products and services with the team's in-depth understanding of the clinical trial industry for enterprises, hospitals and other clients, and continue to contribute to the Chinese pharmaceutical industry.
About Med-Fine Capital
Founded in 2014 at China's financial hub-Shanghai, Med-Fine Capital is an investment fund. Currently, it manages11 investment funds, of which the amount value has reached to nearly 800 million yuan.
Med-Fine Capital mainly invests in the healthcare and bioscience industry. The financial services include equity investments (VC/PE), PIPE, FOF (Fund of Funds), securities investing, M&A and etc.